MedTrace Logo

Study of XIAP Antisense for Advanced Cancers

NCT00385775 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-08-21

No results posted yet for this study

Summary

This study is designed to find the maximum tolerated dose, safety and toxicity profile, and to identify any dose limiting toxicities of AEG35156 administered in 2-hour infusions to patients with advanced cancers.

Conditions

Interventions

DRUG

AEG35156

weekly IV solution infused over 2 hrs

Sponsors & Collaborators

  • Aegera Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jacques Jolivet, MD · Aegera Therapeutics Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-10-31
Completion
2008-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00385775 on ClinicalTrials.gov